April 2023 in “Journal of Investigative Dermatology”
In this study, Aminoacridine, Abemaciclib, and the combination of Aminoacridine with Minoxidil showed potential for effective hair regeneration by activating Wnt/β-catenin signaling in animal experiments.
January 2000 in “วารสารเภสัชวิทยา (Thai Journal of Pharmacology)”
This article reviews treatments for hereditary hairloss using finasteride and minoxidil, which the authors note have an additive effect when combined, but it provides no new clinical results.
This abstract reviews existing hairlosstreatments, highlighting FDA-approved drugs like Minoxidil and Finasteride while noting growing interest in herbal alternatives due to concerns about potential long-term side effects.
72 citations
,
June 2017 in “Zenodo (CERN European Organization for Nuclear Research)”
This article reviews conventional and alternative treatments for hairloss, noting FDA-approved drugs like Minoxidil and Finasteride, but reports no new clinical findings; the authors highlight concerns about side effects, spurring interest in herbal remedies.
A new hairloss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.
PP405 is a potential hairlosstreatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.
Some people don't see results with FDA-approvedhairlosstreatments like finasteride or minoxidil due to underlying issues. The video suggests addressing these issues, especially if there are atypical symptoms or other health conditions.
RU58841 is discussed as a hairlosstreatment, with concerns about potential heart risks and systemic side effects. Some users suggest trying FDA-approvedtreatments like finasteride first, while others debate the safety and cost-effectiveness of RU58841.
The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hairloss.
How does tofacitinib differ when used orally versus topically in hairlosstreatment research?Oral tofacitinib acts on immune signalling throughout the body and has the stronger regrowth evidence in alopecia areata, alongside an FDA boxed warning; topical tofacitinib aims to act only on the scalp, but the human evidence is a handful of small compounded-formulation studies with no large randomized trial. Neither route is approved for hair loss, and regrowth generally reverses after treatment stops.
What is tofacitinib, and why is it discussed in relation to autoimmune-related hairloss such as alopecia areata?Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.
Alfatradiol: What does a form of estrogen have to do with hairloss in men?Alfatradiol (17α-estradiol) is a prescription topical hormone, licensed for androgenetic alopecia in Germany but not FDA-approved. The controlled trial evidence is in women, where it produced stabilisation rather than regrowth and was outperformed by minoxidil; no comparable placebo-controlled trial in men appears to have been published.
How does bimatoprost compare to minoxidil for hair regrowth?Minoxidil is FDA-approved for scalp hair loss and backed by decades of large trials; bimatoprost is approved only for eyelashes, and the published scalp evidence is limited to small short studies, so on the scalp it is off-label and experimental.
How is Fluridil different from other DHT blockers like finasteride?Fluridil is a topical androgen-receptor blocker applied to the scalp, while finasteride is an oral 5-alpha-reductase inhibitor that lowers DHT throughout the body. Finasteride is FDA-approved and far better studied; Fluridil rests on one 43-man trial and is not licensed as a hair-loss medicine, so its long-term safety and effect size are unknown.